despit
avail
effect
antivir
drug
influenza
caus
million
sever
ill
death
industri
world
annual
two
class
drug
current
licens
use
influenza
adamantan
amantadin
rimantadin
target
ion
channel
neuraminidas
inhibitor
nai
target
viral
sialidas
adamantan
class
drug
limit
effect
current
circul
strain
influenza
due
emerg
resist
resist
nai
widespread
becom
concern
popul
use
frequent
treatment
influenza
addit
nai
expens
readili
avail
mani
part
world
therefor
intens
interest
urgenc
develop
new
therapeut
implement
treatment
influenza
recent
seri
vitro
studi
suggest
antimalari
drug
chloroquin
may
activ
influenza
emerg
respiratori
pathogen
chloroquin
lysosomotrop
agent
accumul
endosom
compart
impair
acidif
endosom
prevent
conform
chang
associ
viral
fusion
releas
cytosol
addit
effect
seen
endosom
compart
drug
also
impair
viral
replic
inhibit
lowphdepend
proteas
golgi
would
particip
glycosyl
nascent
viral
protein
step
vital
effici
replic
product
viral
product
clinic
trial
patient
human
immunodefici
viru
demonstr
addit
chloroquin
exist
treatment
protocol
decreas
product
infecti
particl
dose
physiolog
rang
malaria
use
chloroquin
patient
led
author
specul
potenti
util
treatment
viral
infect
chloroquin
found
efficaci
vivo
use
would
sever
attract
featur
includ
uniqu
mechan
action
lack
crossresist
antivir
drug
low
cost
widespread
worldwid
avail
goal
studi
determin
whether
chloroquin
could
decreas
morbid
influenza
viru
infect
two
relev
anim
model
mous
ferret
two
virus
util
mice
mouseadapt
mount
sinai
strain
puerto
rico
subtyp
viru
taken
influenza
viru
repositori
st
jude
children
research
hospit
determin
whether
find
subtyp
specif
second
viru
gener
use
eight
plasmid
revers
genet
system
contain
hemagglutinin
ha
neuraminidas
na
hong
kong
six
intern
gene
describ
backbon
util
enhanc
virul
mice
wildtyp
parent
caus
mild
diseas
lethal
virus
grown
madindarbi
canin
kidney
mdck
cell
conduct
mous
studi
suscept
virus
chloroquin
vitro
assess
cell
infect
multipl
infect
virus
hour
presenc
absenc
lm
chloroquin
cell
collect
hour
postinfect
stain
antiha
surfac
ha
express
assess
flow
cytometri
report
previous
chloroquin
effect
vitro
reduc
percentag
cell
express
ha
lm
concentr
compar
treatment
lesser
reduct
lm
data
shown
determin
whether
chloroquin
effect
vivo
test
drug
establish
mous
model
infect
use
age
weight
match
group
femal
balb
c
mice
chloroquin
given
daili
start
hour
prior
infect
dose
base
prior
publish
protocol
evalu
use
protect
mice
cpg
lipopolysaccharid
exposur
group
nine
mice
infect
intranas
volum
steril
pb
light
isofluran
inhal
anesthesia
either
tcid
mld
tcid
mld
mice
treat
daili
day
termin
experi
either
intratrach
oral
mg
kg
day
chloroquin
sucros
vehicl
mock
treat
sucros
alon
follow
weight
loss
differ
weight
loss
seen
day
postinfect
anova
p
follow
infect
either
viru
intratrach
figur
oral
data
shown
treatment
follow
neg
result
dose
escal
attempt
use
mg
kg
day
group
five
mice
infect
chloroquin
improv
weight
loss
associ
influenza
viru
infect
highest
dose
mice
lost
significantli
weight
day
treat
chloroquin
compar
group
figur
p
anova
thu
chloroquin
effect
prevent
amelior
influenza
mice
dose
rang
test
influenza
viru
could
detect
lung
anim
day
indic
worsen
diseas
mg
kg
day
dose
due
enhanc
prolong
replic
viru
anim
experi
perform
facil
anim
resourc
center
st
jude
children
research
hospit
sjcrh
experi
conduct
accord
guidelin
set
anim
care
use
committe
sjcrh
character
effect
chloroquin
model
system
close
repres
human
infect
test
drug
young
adult
ferret
four
femal
young
adult
g
ferret
given
daili
oral
dose
mg
kg
day
chloroquin
volum
sucros
start
hour
prior
infect
infect
intranas
tcid
wildtyp
influenza
viru
sydney
compar
untreat
anim
infect
follow
similar
manner
viral
dose
deriv
previou
ferret
studi
use
strain
chloroquin
dose
use
approxim
dose
given
children
malaria
treatment
ferret
group
exhibit
clinic
sign
consist
influenza
includ
decreas
activ
sneez
copiou
nasal
discharg
differ
temperatur
protein
content
nasal
wash
viral
titer
nasal
wash
day
test
except
day
viral
nasal
wash
titer
significantli
higher
control
group
chloroquinetr
group
figur
overal
howev
prevent
therapi
dose
mg
kg
day
chloroquin
start
hour
prior
infect
follow
weight
loss
mean
sd
compar
mocktreat
anim
b
group
five
mice
infect
dose
either
mg
kg
day
chloroquin
start
hour
prior
infect
follow
weight
loss
compar
mocktreat
anim
asterisk
indic
signific
differ
weight
loss
compar
group
time
point
p
anova
author
chloroquin
appear
littl
effect
influenz
infect
ferret
conclus
found
although
chloroquin
effect
vitro
limit
replic
virus
express
either
ha
concurr
publish
report
effect
extend
vivo
model
influenza
concentr
mg
kg
day
abl
protect
mice
signific
weight
loss
follow
infect
either
higher
concentr
effect
viral
infect
enhanc
treat
mice
lost
weight
mocktreat
anim
studi
explor
prophylact
effect
chloroquin
ferret
model
system
close
match
human
infect
likewis
demonstr
signific
posit
effect
possibl
higher
dose
chloroquin
analog
hydroxychloroquin
potenti
better
pharmacokinet
may
benefici
effect
unabl
elicit
model
studi
combin
therapi
current
antiinfluenza
drug
chloroquin
may
also
use
develop
effect
therapi
treatment
prophylaxi
influenza
howev
confirm
find
studi
laboratori
like
significantli
dampen
enthusiasm
use
chloroquin
antivir
influenza
author
declar
conflict
interest
